National Cancer Institute (NCI)
ACRIN is one of 12 clinical trials cooperative groups receiving funding from the NCI to conduct research studies that evaluate new cancer treatments, explore methods of cancer prevention and early detection, and study quality-of-life issues and rehabilitation during and after treatment. Cooperative groups include researchers, cancer centers, and community physicians throughout the United States, Canada, and Europe. They place more than 22,000 new patients into cancer treatment clinical trials each year. In 1999, ACRIN became the only group in this program focusing on the use of imaging technology in cancer research.
To access general information on cancer prevention, diagnosis, treatment, statistics, research, clinical trials, and news, visit the NCI Web site at http://www.cancer.gov/. To talk with an information specialist from the NCI's Cancer Information Service (English or Spanish), within the United States, Monday through Friday 9:00 a.m. to 4:30 p.m. local time, call 1-800-4-CANCER / (1-800-422-6237). You can also have a confidential online text chat with an NCI information specialist—Monday through Friday 9:00 a.m. to 11:00 p.m. U.S. Eastern Time—by clicking here: <LiveHelp>.
The Avon Foundation, a nonprofit foundation that supports clinical care, research, and education related to breast cancer, has provided a grant of approximately $5.2 million to ACRIN in support of two ACRIN breast cancer initiatives. The majority of the grant is going toward funding ACRIN 6666, a trial of ultrasound screening for breast cancer in a high-risk population. The Principal Investigator is Dr. Wendie Berg, who practices at Johns Hopkins, Greenspring. She leads a multidisciplinary team of breast imagers, statisticians, health outcomes specialists, and ACR Headquarters staff in the development and execution of this trial.
ACRIN Fund for Imaging Innovation
In 2005, the ACRIN Fund for Imaging Innovation was established to supplement the ongoing levels of funding ACRIN receives from NCI. This capital campaign is designed to stabilize the clinical trials infrastructure, enabling ACRIN to increase the number of trials and their degree of comprehensiveness; fund new trials of key emerging technologies; and disseminate critical study results to oncologists, payers, and government agencies. Efforts directed toward industry and the radiology community have secured over $7 million.